Current Treatment Options in Neurology

, Volume 11, Issue 4, pp 297–305

Glioblastoma multiforme

Authors

  • Mary Welch
    • The Neurological Institute of Columbia University
Article

DOI: 10.1007/s11940-009-0033-5

Cite this article as:
Welch, M. & Lai, R. Curr Treat Options Neurol (2009) 11: 297. doi:10.1007/s11940-009-0033-5
  • 186 Views

Opinion statement

Optimal management of newly diagnosed glioblastoma multiforme includes maximal surgical resection, followed by 60 Gy of external beam radiation plus concomitant daily temozolomide and at least six additional monthly cycles of maintenance temozolomide. Several large phase 3 trials are now ongoing to determine whether agents added to this regimen may confer further survival advantage. At the time of disease recurrence, bevacizumab is the most commonly used agent. Whenever feasible, patients should be encouraged to participate in clinical trials, which are currently focused on antiangiogenic and targeted therapies.

Copyright information

© Current Medicine Group, LLC 2009